Medizinische Universität Graz - Research portal
Selected Publication:
Zobel, G; Dacar, D; Rödl, S; Friehs, I.
Inhaled nitric oxide versus inhaled prostacyclin and intravenous versus inhaled prostacyclin in acute respiratory failure with pulmonary hypertension in piglets.
PEDIAT RES 1995 38: 198-204.
Doi: 10.1203/00006450-199508000-00011
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Leading authors Med Uni Graz
- Zobel Gerfried
- Co-authors Med Uni Graz
- Dacar Drago
- Roedl Siegfried
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- This study was a prospective, randomized design to compare oxygenation and pulmonary hemodynamics between inhaled nitric oxide (NO) and inhaled prostacyclin (PGI2), and between inhaled and i.v. PGI2 in acute respiratory failure with pulmonary hypertension. Acute respiratory failure with pulmonary hypertension was induced in 12 piglets weighing 9-12 kg by repeated lung lavages and a continuous infusion of the stable endoperoxane analogue of thromboxane. Thereafter the animals were randomly assigned either for NO or PGI2 application. All animals were treated with different concentrations of NO or different doses of PGI2 applied i.v. and inhaled in random order. Continuous monitoring included ECG, central venous pressure (CVP), mean pulmonary artery pressure (MPAP), mean arterial pressure (MAP), arterial oxygen saturation (SaO2), and mixed venous oxygen saturation (SvO2) measurements. NO inhalation of 10 ppm resulted in a significant increase in PaO2/fraction of inspired oxygen (FiO2) from 7.8 +/- 1.34 kPa to 46.1 +/- 9.7 kPa. MPAP decreased significantly from 5.1 +/- 0.26 kPa to 3.7 +/- 0.26 kPa during inhaled NO of 40 ppm; i.v. infusion of PGI2 slightly increased oxygenation parameters. A significant increase in PaO2/FiO2 up to 32.4 +/- 3.1 kPa was observed during PGI2 aerosol delivery (p < 0.01); i.v. PGI2 decreased MAP from 11.5 +/- 0.39 kPa to 9.8 +/- 0.66 kPa (p < 0.05) and MPAP from 5.8 +/- 0.53 kPa to 4.5 +/- 0.66 kPa, respectively (p < 0.05). PGI2 aerosol delivery significantly decreased the MPAP to 3.7 +/- 0.53 kPa (p < 0.05) without influencing the MAP.(ABSTRACT TRUNCATED AT 250 WORDS)
- Find related publications in this database (using NLM MeSH Indexing)
- Acute Disease -
- Administration, Inhalation -
- Animals -
- Comparative Study -
- Disease Models, Animal -
- Epoprostenol - therapeutic use
- Evaluation Studies - therapeutic use
- Female - therapeutic use
- Hemodynamic Processes - drug effects
- Hypertension, Pulmonary - drug therapy
- Male - drug therapy
- Nitric Oxide - therapeutic use
- Random Allocation - therapeutic use
- Research Support, Non-U.S. Gov't - therapeutic use
- Respiratory Insufficiency - complications
- Swine - complications